Ransom Advisory’s Globus Medical GMED Stock Holding History

Ransom Advisory’s Portfolio GMED Stock Details GMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$1.57K	Hold	18	–	–	﹤0.01%	405
2025 Q3	$1.03K	Hold	18	–	–	﹤0.01%	283
2025 Q2	$1.06K	Hold	18	–	–	﹤0.01%	306
2025 Q1	$1.32K	Hold	18	–	–	﹤0.01%	312
2024 Q4	$1.49K	Hold	18	–	–	﹤0.01%	387
2024 Q3	$1.29K	Hold	18	–	–	﹤0.01%	389
2024 Q2	$1.23K	Buy	+18	New	+$1.07K	﹤0.01%	385

Other funds holding GMED

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ransom Advisory's GMED Position: Q4 2025 in Review

Ransom Advisory held its Globus Medical (GMED) position steady in Q4 2025 at 18 shares worth $1.57K. The position accounts for ﹤0.01% of the portfolio, ranked #405.

Ransom Advisory first reported a position in GMED in Q2 2024 and has held it in 7 quarters since. 561 funds tracked by Wall St. Rank hold GMED as of Q4 2025.

Ransom Advisory held 18 shares of Globus Medical worth $1.57K as of Q4 2025.
Ransom Advisory left its Globus Medical share count unchanged in Q4 2025.
Globus Medical made up ﹤0.01% of Ransom Advisory's portfolio in Q4 2025, its #405 holding.
Ransom Advisory first reported a position in Globus Medical in Q2 2024 and has held it in 7 quarters since.
561 funds tracked by Wall St. Rank held Globus Medical as of Q4 2025.

Based on Ransom Advisory's 13F filing for Q4 2025, filed 6 Jan 2026.